---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061208"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-09-10T10:02:31+00:00"
generated_at: "2026-09-10T10:05:08.217814+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Axogen acquires BioCircuit for $200M cash, funds via $208.7M stock offering

## Summary
- Acquires BioCircuit for $200M cash; $1M withheld for post-closing adjustments; close expected Q4 2026.
- Adds NerveTape, first FDA-approved sutureless nerve repair device; spin-out of BioCircuit's electronics business before close.
- Priced 4.91M shares at $42.50/share for ~$208.7M gross; underwriters have 30-day option for 736,500 more.
- Deal expected accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in first year post-close.
- No regulatory approvals required; financing not conditioned on deal; if deal fails, proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001628280-26-061208
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-09-10T10:02:31+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/0001628280-26-061208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/axgn-20260909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061208
- JSON: https://secwatch.observer/filing/0001628280-26-061208.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.